• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

LonGieva Therapeutics

Wednesday, June 05, 2024
Start-Up Stadium Session
CNS/Neurological
Longieva has been developing novel therapeutics for validated targets for CNS disorders with utility in neurodegeneration (such as Alzheimer's and Parkinson's) and addictive disorders. We believe the therapy also offers the potential to treat some psychiatric disorders. These projects are based on the composition of novel chemical entities (small molecules) and associated IP. Exciting new data generated in Stanford lab supports the vast potential of these projects. Longieva Therapeutics has been formed to advance these projects and are now initiating funding discussions with potential partners. One of our programs is fully supported by NIH non-dilutive funding from the Blueprint Neurotherapeutics network for preclinical and clinical development up to phase III for drug addiction indications. This is our most advanced program. We plan to develop the utilities in other CNS indications through funding activity and partnership.

Company HQ City

Menlo Park

Company HQ State

CA

Company HQ Country

United States

CEO/Top Company Official

Mehrdad Shamloo
Speakers
Mehrdad Shamloo
Back to Session List

white squarewhite

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS